Navigating Anthem (Elevance Health) Stelara Prior Authorization

Successfully managing prior authorization for high-cost specialty biologics like Stelara (ustekinumab) with Anthem (Elevance Health) requires a clear understanding of payer-specific processes and policy nuances. Klivira provides the operational insights necessary to navigate Anthem (Elevance Health) Stelara prior authorization efficiently.

For revenue cycle directors, prior authorization coordinators, and IT integration leads, the complexity of securing approvals for specialty medications under medical benefits is a significant operational challenge. Stelara, an IL-12/23 inhibitor indicated for conditions such as psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, falls into this category. This page outlines the specific considerations for obtaining prior authorization from Anthem-licensed plans.

Anthem's Prior Authorization Channels for Medical Benefit Drugs

For Stelara, which is typically covered under the medical benefit, Anthem-licensed plans primarily direct prior authorization submissions through Availity Essentials. This multi-payer provider workspace facilitates PA initiation, member benefit lookup, and document uploads. Additionally, X12 278 transactions are supported via clearinghouses, offering an electronic pathway for submission.

Accessing Anthem's Utilization Management Policies for Stelara (Ustekinumab)

Anthem operating companies publish their medical policy and clinical utilization management guideline libraries through provider sites, accessible via Availity. Each state-licensed Anthem plan maintains its own medical-policy index, which aligns with the broader Elevance Health corporate criteria framework. When seeking criteria for ustekinumab, it is critical to reference the specific policy number, the relevant plan-state context, and the effective date to ensure accurate submission.

Electronic Prior Authorization (ePA) Posture

Elevance Health, through its Anthem operating companies, has actively participated in Da Vinci Project initiatives and HL7 connectathons, signaling a commitment to advancing electronic prior authorization. While specific conformance status for Da Vinci PAS, CRD, and DTR requires verification of current public disclosures, Anthem supports X12 278 for medical benefit PA. For pharmacy benefit drugs, CarelonRx (Anthem's in-house PBM) integrates with CoverMyMeds and Surescripts ePA.

Common Denial Reasons and Appeal Pathways for Stelara

Anthem denials are commonly returned via X12 277/835 transactions and through Availity status updates. Frequent denial categories for specialty drugs like Stelara include medical necessity or insufficient documentation, failure to complete step therapy requirements, and site-of-service mismatch. Appeals for standard medical prior authorizations follow the Anthem operating-company appeals process detailed in the provider manual, with peer-to-peer reviews available.

Klivira's Role in Streamlining Anthem Stelara PAs

Klivira integrates directly with EMRs and payer portals, including Availity, to automate the prior authorization workflow for complex medical benefit drugs like Stelara. Our platform helps identify specific Anthem (Elevance Health) policy requirements, streamline documentation submission, and track authorization status, reducing manual effort and improving turnaround times for ustekinumab approvals.

Frequently asked questions

Which Anthem portal is used for Stelara prior authorization?

For Stelara, which is a medical benefit drug, prior authorization requests for Anthem-licensed plans are typically submitted through Availity Essentials. This portal serves as the primary interface for initiating medical benefit PAs and managing supporting documentation.

Are X12 278 transactions supported for Stelara PA with Anthem?

Yes, Anthem-licensed plans accept X12 278 transactions via clearinghouses for medical benefit prior authorization requests, including those for specialty drugs like Stelara (ustekinumab). This provides an electronic submission option for providers.

How do I find the specific medical policy for Stelara under my Anthem plan?

Anthem's medical policies and clinical guidelines are published on their provider websites, accessible through Availity. It is crucial to search for the specific ustekinumab policy by referencing the policy number, your state's Anthem plan, and the effective date, as policies can vary by state and plan type.

What are common reasons for Stelara PA denials from Anthem?

Common denial reasons for Stelara (ustekinumab) from Anthem-licensed plans often include insufficient documentation to support medical necessity, failure to meet step therapy requirements, or issues related to the proposed site of service. Ensuring all clinical criteria are met and thoroughly documented is key.

Does Anthem (Elevance Health) participate in Da Vinci Project initiatives for ePA?

Elevance Health, the parent company of Anthem, has participated in Da Vinci Project initiatives and HL7 connectathons. While this indicates engagement with advanced electronic prior authorization standards, current production conformance status for specific Da Vinci IGs should be verified directly with Anthem or Elevance Health disclosures.